Shares of Biopharmx Corp (NYSEAMERICAN:BPMX) gapped up prior to trading on Tuesday . The stock had previously closed at $0.19, but opened at $0.18. Biopharmx shares last traded at $0.22, with a volume of 27267424 shares trading hands.
Separately, Maxim Group reiterated a “buy” rating and issued a $1.50 price target on shares of Biopharmx in a research note on Friday, December 8th.
The stock has a market capitalization of $22.85, a P/E ratio of -0.93 and a beta of 1.40.
A hedge fund recently bought a new stake in Biopharmx stock. Armistice Capital LLC bought a new position in shares of Biopharmx Corp (NYSEAMERICAN:BPMX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,470,000 shares of the biotechnology company’s stock, valued at approximately $382,000. Armistice Capital LLC owned about 2.72% of Biopharmx as of its most recent filing with the Securities and Exchange Commission.
COPYRIGHT VIOLATION WARNING: “Biopharmx (BPMX) Shares Gap Up to $0.18” was originally published by Ticker Report and is the sole property of of Ticker Report. If you are accessing this news story on another domain, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this news story can be read at https://www.tickerreport.com/banking-finance/3230082/biopharmx-bpmx-shares-gap-up-to-0-18.html.
BioPharmX Corporation is a specialty pharmaceutical company. The Company is focused on utilizing its drug delivery technologies to develop and commercialize prescription and over-the-counter (OTC) products that address markets in women’s health and dermatology. Its portfolio of product candidates includes two clinical stage product candidates: BPX01, which is a topical antibiotic for the treatment of acne based on a formulation of minocycline, and BPX03, which is a molecular iodine (I2) tablet for the treatment of benign breast pain associated with fibrocystic breast condition (FBC) and cyclic mastalgia.
Receive News & Ratings for Biopharmx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biopharmx and related companies with MarketBeat.com's FREE daily email newsletter.